Airway Responsiveness to Adenosine 5′-Monophosphate and Exhaled Nitric Oxide Measurements
Airway responsiveness to AMP was assessed using a standardized dosimetric method, as described in detail previously. AMP (Sigma Chemical; St. Louis, MO) was dissolved freshly in 0.9% saline solution to produce a doubling concentration range of 0.39 to 400 mg/mL. Each solution was administered from a jet nebulizer attached to a breath-activated dosimeter (model MB3; Mefar; Brescia, Italy) at a nebulization time of 1 s with a pause time of 6 s. The nebulizer delivers particles with an aerodynamic mass median diameter of 3.5 to 4.0 pm at an output of 10 pL per breath. Patients inhaled the aerosolized AMP solutions in five inhalations from functional residual capacity to total lung capacity through a mouthpiece with the patient’s nose clipped. Normal saline solution was inhaled initially, followed by five breaths of doubling concentrations of AMP at 2- to 3-min intervals. Single measurements of FEVl were made 60 to 90 s after the inhalation of each concentration, unless the forced expiratory maneuver was judged to be technically unsatisfactory. The test was interrupted when a fall in FEVl of at least 20% from the post-saline solution value was recorded or the maximum concentration had been administered. The PC20 was calculated using a formula given by Cockcroft.
ENO Measurement Technique
ENO concentration was measured on-line by the restricted-breath analysis according to the recommendations of the American Thoracic Society using a chemiluminescence analyzer (NiOx; Aerocrine; Solna, Sweden), as described in detail previously. Briefly, the patient was instructed to inhale through the mouth to total lung capacity and immediately exhale through the mouthpiece against a fixed resistance. Patients inhaled ambient air that was passed through a filter to reduce inhaled nitric oxide concentrations to < 5 parts per billion (ppb). Maintenance of a constant flow was achieved using a visual feedback display on the computer screen. A flow rate of 45 mL/s was used. An exhalation of 10 s with a plateau of at least 3 s in duration was required to calculate the nitric oxide plateau. Patients repeated the maneuver until three acceptable tests were performed, and the average of the three plateau values was recorded.
Data were analyzed with standard statistical software packages (SPSS, version 10.0 for Windows; SPSS; Chicago, IL; and InStat for Windows, version 3.00; GraphPad Software; San Diego, CA). Variability in PEF was calculated with the following formula: (maximum PEF – minimum PEF)/mean PEF of the day X 100. All PC20 and ENO values were log-transformed before analysis and presented as geometric means with 95% confidence intervals (CIs). All other numerical variables are reported as arithmetic means with 95% CI.
Comparisons of the baseline characteristics between groups were performed by unpaired t tests for continuous data and by Fisher exact tests for categorical data. Possible predictors for failure of ICS reduction were determined using log-rank test. Kaplan-Meier survival curves were used to demonstrate the probability of failure of ICS reduction between subjects with increased and those with normal responsiveness to AMP, and between patients with normal ENO concentrations and those with increased ENO. For PC20, the cut-off points evaluated were 400 mg/mL at baseline and one doubling concentration increase over the baseline value 2 weeks after the dose of ICS was halved.
Specific ENO cut-off points evaluated included 15 ppb, 20 ppb, and 30 ppb at baseline, and 10 ppb increase over the baseline value 2 weeks after the dose of ICS was halved. Logistic parameters were estimated using maximum likelihood estimation and evaluated using the likelihood ratio test. Odds ratios (ORs) with a CI > 1 indicate a significantly increased risk for failure of ICS reduction. Correlations were assessed using the Pearson correlation coefficient; p values are two sided, and values < 0.05 were considered statistically significant.
Forty-seven patients were initially selected, but data from only 37 patients were analyzed. Four patients did not strictly fulfill entry criteria, two patients declined the previous acceptance of participation, two patients were unavailable for follow-up, and in two patients an error was made in performing the AMP challenge. Table 1 shows baseline characteristics of the 37 patients studied; 19 of the 37 patients had bronchoconstriction in response to AMP.
Twenty-seven patients did not have exacerbations when the dose of ICS was halved, whereas 10 patients had an asthma exacerbation: 2 patients after 3 weeks, 3 patients after 4 weeks, 1 patient after 6 weeks, 1 patient after 8 weeks, 2 patients after 9 weeks, and 1 patient after 11 weeks of treatment with a reduced dose of ICS. Six patients had exacerbations reflected by nocturnal awakening, four patients had exacerbations reflected by a decrease in morning PEF of > 20%, and five patients had exacerbations reflected by an increased use of inhaled albuterol. Five patients fulfilled two or more criteria at the time of the exacerbation. None had severe exacerbations that required hospital admission.
Table 1—Subject Characteristics at Baseline*
|Age, yr||32.2 (28.7-35.6)|
|Duration of asthma, yr||16.8 (13.9-19.7)|
|Skin test result positive||30|
|Duration of ICS use, mo||27.7 (19.0-36.5)|
|ICS dose, pg/d (beclomethasone equivalent)! ICS drug||619 (510-728)|
|FEV1 % predicted||96.8(92.2-101.3)|
*Data are presented as No. or mean (95% CI). fBeclomethasone dipropionate equivalent dose of ICS was calculated on the basis of fluticasone propionate being twice as potent as beclomethasone dipropionate or budesonide, so that the equivalent fluticasone propionate dose was multiplied twofold.
PC20 at the time of exacerbations was not determined in two patients for safety reasons.
There were no significant differences in clinical characteristics, pulmonary function, or ENO levels at baseline between the groups that did and did not have exacerbations (Table 2). A higher responsiveness to inhaled AMP was found in patients with exacerbations, but this difference was of marginal significance (p = 0.07).
Predictive Power Using Baseline Data Before Steroid Dose Reduction
Having both bronchoconstriction in response to AMP and increased ENO levels (cut-off points, 15 ppb or 20 ppb) was a significant predictor for failure in ICS reduction (Fig 1). By contrast, having either bronchoconstriction in response to AMP or increased ENO levels alone was not a predictor for failure of ICS reduction. The ORs for failure of ICS reduction (Table 3) were 8.17 (95% CI, 1.60 to 41.64; p < 0.05) for the presence of both AMP bronchoconstriction and increased ENO levels at a cut-off point of 15 ppb, and 5.25 (95% CI, 1.11 to 24.91; p < 0.05) for the presence of both AMP bronchoconstriction and increased ENO levels at a cut-off point of 20 ppb.
Predictive Power Using the Modifications After 2 Weeks of ICS Dose Reduction
Figure 2 shows the survival curve using the modifications of PC20 and ENO values 2 weeks after the dose of ICS was halved. Having a decrease in PC20 (cut-off point, one doubling concentration) was a borderline significant predictor for failure of ICS reduction (p = 0.062), whereas having an increase in ENO levels (cut-off point, 10 ppb) was not a predictor for failure of ICS reduction. Only three patients showed both a decrease in PC20 values greater than or equal to one doubling concentration and an increase in ENO > 10 ppb.
Correlations between the changes from baseline in PC20 that occurred during an exacerbation (group with exacerbation) or at the end of study period (group without exacerbation), and the changes in symptoms, albuterol use, lung function, and ENO levels are presented in Table 4. Data from both patient groups were pooled for analysis of correlation. There were significant correlations between the changes in PC20 values with the changes in daytime symptom scores (r = 0.41, p = 0.02) and amount of albuterol use (r = 0.43, p = 0.009), but no significant correlation was found between the changes in PC20 and the changes in either ENO levels, nighttime symptom scores, or pulmonary function. Furthermore, the changes in ENO values were not significantly related with the changes in either clinical manifestations or pulmonary function.
The results of the present study suggest that, in asthmatic patients with their disease already stabilized and well controlled by use of ICS, measurements of AMP responsiveness and ENO levels can be used to predict the success or failure of reduction in ICS dose.
Article by Canadian Health Care Mall.